/
| GEL thousands | 2023¹ | 2024 | 2025 |
|---|---|---|---|
| P&L Items | |||
| Revenue | 68,669 | Register | Register |
| Adj. Operating Profit² | 3,027 | Register | Register |
| Adj. EBITDA² | 12,707 | Register | Register |
| Net Income | (1,722) | Register | Register |
| Margins & Profitability Ratios (%) | |||
| Adj. Operating Profit Margin² | 4.4% | Register | Register |
| Adj. EBITDA Margin² | 18.5% | Register | Register |
| Net Income Margin | -2.5% | Register | Register |
| Balance Sheet Items & Leverage | |||
| Total Assets | 161,926 | Register | Register |
| Total Debt³ | 71,891 | Register | Register |
| Total Debt³ / Adj. EBITDA² | 5.66x | Register | Register |
| Total Equity | 73,332 | Register | Register |
| ROAE | -2.3% | Register | Register |
¹ 2023 figures are those of the predecessor group (JSC Evex Clinics), which still included the general-hospitals segment transferred to JSC Georgian Clinics on 11 January 2024; from 2024 the figures cover the polyclinics business only.
² Adj. Operating Profit has been adjusted to exclude non-recurring and one-time items. Adj. EBITDA is calculated by adding back D&A expenses to the adjusted operating profit.
³ Total debt includes lease liabilities, where applicable.